To assess the efficacy, safety, and tolerability of lasmiditan 50 mg, 100 mg, and 200 mg compared to placebo in the treatment of a single migraine attack.
Criteria:Be at least 6 and less than 18 years of age at first screening.
Have a minimum body weight of 15kg (33 lbs)
Have history of a migrane with or without an aura.
Be able to swallow a tablet.